… of additional EGFR mutations, novel TP53 mutations, c-Met amplification, PIK3CA mutation,
and … This pattern is generally similar to that found in cases with common EGFR mutations that …

… It was recently approved for the first-line treatment of EGFR mutation-positive NSCLC (Del19
or L858R) based on the results from the phase III ARCHER 1050 trial (dacomitinib vs. …

… The results of comparing the EGFR‐TKI with standard platinum‐based doublet chemotherapy
as the first‐line treatment in advanced NSCLC patients with activated EGFR mutation were …

… EGFR TKI that potently and selectively inhibits both EGFRm and EGFR T790M resistance
mutations … PFS than comparator EGFR TKIs (erlotinib or gefitinib) in the first-line treatment of …

… In conclusion, different subtypes of EGFR mutations especially exon 19 deletions demonstrated
differential PFS outcomes after first-line TKI therapy. This finding cautions that not all …

… Patients with EGFR mutations other than gefitinib-sensitive mutations did not respond well
… with atypical EGFR mutations (mutations other than exon 19 deletions and L858R mutation) …

… first-line TKI therapy or first-line chemotherapy followed by second-line TKI therapy for
sensitive EGFR mutated … ) in terms of efficacy and safety as first-line therapy in this population. …

… In ENSURE, efficacy was analyzed according to type of EGFR mutation. The interaction term
for EGFR mutation type and treatment demonstrated statistical significance (P = 0.0187) for …

… a first-line treatment of Caucasian patients with EGFR mutation… characteristics and baseline
tumour EGFR mutation status. Pre… of baseline tumour and plasma EGFR mutation status in all …

… TKIs versus patients who receive third-generation EGFR TKIs in the first line. This is an
area of unmet need and will be required to provide definitive evidence of whether it is …